Continuing the series of webinar discussing developments in the UK Biopharma sector, their impact on employment opportunities and potential solutions to create growth in the future. 

The webinar will look at the balance of investment between discovery research and clinical development support in the UK, be that from government, charity or private capital pools. As private investors have trended towards later stage opportunities and TechBio approaches have impacted drug discovery strategies lab-based scientific roles have been compromised. Whether incentivising clinical development in the UK will secure greater retention of discovery research or whether continued discovery research funding will anchor the clinical development pipeline in the UK as companies scale-up will be discussed along with the potential impact on the employment, required skills and how individuals can move with demand.

*Agenda:
16.00 – Welcome, Tony Jones, One Nucleus 
16.05 – Who is funding what at the current time?
David Montgomery, PM Life Sciences Consulting
16.10 – Why funding drug discovery research in the UK matters
Matthew Fyfe, Outrun Therapeutics
16.15 – Why fixing the clinical development environment in the UK matters
Sheuli Porkess, PM Life Sciences Consulting
16.20 – Open Q&A
16.50 – Aligning skills with an evolving drug discovery and development industry
Natasha Robbins, BioTc Search
17.00 – Close 
*Subject to change.
 
Registration:
Free for all to attend but pre-registration essential.